Key clinical point: About 50% of patients with facial vitiligo who were on the two highest doses of topical ruxolitinib had a 50% decrease in depigmentation after 6 months of treatment.
Major finding: At 24 weeks, 50% on ruxolitinib cream 1.5% once daily had 50% clearing, as did 45.5% of those on ruxolitinib cream twice daily (P less than .0001 vs. placebo for both).
Study details: Randomized, double-blind, vehicle-controlled phase 2b study of 157 adult patients with facial and body vitiligo.
Disclosures: Dr. Rosmarin reported financial relationships with numerous pharmaceutical companies, including Incyte, which funded the study.
REPORTING FROM WCD2019